Tannic acid and vitamin E loaded PLGA nanoparticles ameliorate hepatic injury in a chronic alcoholic liver damage model via EGFR-AKT-STAT3 pathway.
Aim: Tannic acid and vitamin E loaded-poly D, L-lactide-co-glycolic acid (PLGA) nanoparticles (NP) were developed to achieve hepatoprotection in alcoholic liver disease mice model. Materials & methods: PLGA NPs were formed by emulsion solvent evaporation and characterized and delivered to mice. Histology studies were performed, serum enzyme levels of AST, ALT and inflammatory cytokines were checked using ELISA kits. Confocal microscopy and western blot analysis were utilized to determine protein expression levels, and docking studies were performed for interaction analysis. Results: PLGA NPs provided hepatoprotection by reducing inflammatory load, preventing reactive oxygen species generation and apoptosis, as well as by inhibiting the EGFR-AKT-STAT3 pathway. Conclusion: PLGA NPs of tannic acid and vitamin E could be a future medication for alcoholic liver disease treatment.